2022
TREM2 Deficiency Disrupts Network Oscillations Leading to Epileptic Activity and Aggravates Amyloid-β-Related Hippocampal Pathophysiology in Mice
Stoiljkovic M, Gutierrez KO, Kelley C, Horvath TL, Hajós M. TREM2 Deficiency Disrupts Network Oscillations Leading to Epileptic Activity and Aggravates Amyloid-β-Related Hippocampal Pathophysiology in Mice. Journal Of Alzheimer's Disease 2022, 88: 837-847. PMID: 34120899, PMCID: PMC8898080, DOI: 10.3233/jad-210041.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseMicroglial functionTREM2 functionTheta-phase gamma-amplitude couplingHippocampal network functionSpontaneous epileptiform seizuresNetwork oscillationsTransgenic AD modelHippocampal neuronal excitabilityMyeloid cells 2Clinical Alzheimer's diseaseWild-type miceHippocampal network oscillationsHippocampal pathophysiologyProgressive dementiaTau pathologyUrethane anesthesiaAD pathophysiologyNeuronal excitabilityEpileptiform seizuresEpileptic activityAD modelTREM2Disease pathologyCells 2
2021
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. Therapy for Alzheimer’s disease: Missing targets and functional markers? Ageing Research Reviews 2021, 68: 101318. PMID: 33711510, PMCID: PMC8131215, DOI: 10.1016/j.arr.2021.101318.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseNew symptomatic treatmentsNeural network integrityClinical characteristicsNext-generation therapiesSymptomatic treatmentOutcome biomarkerTau pathologyFluid biomarkersPlasma biomarkersDisease progressionEffective therapyNeurophysiological biomarkersTreatment candidatesCerebrospinal fluidNovel biomarkersTranslational studiesTreatment interventionsDiseaseTarget engagementTherapyBiomarkersCurrent conceptsMultiple biomarkersDrug targets